Aptus Pharma's IPO listed on September 30th on BSE and NSE at ₹80.80 with a 15.4% premium. The company is active in the marketing and distribution of finished pharmaceutical formulations. The IPO size was ₹13.02 crore and it was subscribed 22.27 times. In FY 2025, the company's revenue was ₹24.64 crore and net profit was ₹3.10 crore.
Aptus Pharma Listing: Aptus Pharma's IPO opened from September 23-25, 2025, and listed on September 30th on BSE and NSE at a price of ₹80.80 with a 15.4% premium. The company is in the business of marketing and distribution of finished pharmaceutical formulations. The IPO size was ₹13.02 crore and it received 22.27 times subscription. Prior to the IPO, the company had raised ₹3.70 crore from anchor investors. In FY 2025, the company's revenue was ₹24.64 crore and net profit was ₹3.10 crore, which is 38% and 288% higher, respectively, compared to the previous year.
IPO Details and Subscription
Aptus Pharma's ₹13.02 crore public issue was open between September 23 and 25. A total of 19 lakh new shares were issued. In the IPO, the reserved portion for Qualified Institutional Buyers was subscribed 1.24 times, for Non-Institutional Investors 28.75 times, and for Retail Investors 31.43 times. Overall, the IPO was subscribed 22.27 times, indicating growing investor interest in the company.
Prior to the IPO, the company had raised ₹3.70 crore from anchor investors. This step proved crucial to the success of the IPO and helped boost investor confidence.
Company's Business and Promoters
Aptus Pharma is active in the business of marketing and distribution of finished pharmaceutical formulations. The company's promoters include Tejash Maheshchandra Hathi, Chaturbhuj Vallabhbhai Butani, Kapilbhai Hasmukhbhai Chandrana, Ghanshyam Vinubhai Pansuriya, Milli Chetan Lalseta, Riddhish Natvarlal Tanna, Gaurang Rameshchandra Thakkar, Kripaliben Mayank Thakkar, and Kunjal Piyushbhai Unadkat. The long-standing activity of these promoters in the pharma sector has increased investor confidence.
Strong Financial Performance
In FY 2025, Aptus Pharma recorded a 38 percent increase in revenue. The company's revenue grew to ₹24.64 crore, up from ₹17.88 crore last year. During the same period, net profit also surged by 288 percent, reaching ₹3.10 crore. In the previous financial year, FY 2024, the net profit was merely ₹80 lakh.
Aptus Pharma's financial health appears b, although the company had a debt of ₹10.36 crore in FY 2025. Experts believe that with increasing sales and profits, managing this debt could be challenging, but the company's marketing and distribution network are capable of handling it.
Share Price Increase During Listing
During the IPO listing, a gain of over 15 percent in shares boosted investor enthusiasm. Investors considered this a positive sign and saw an investment opportunity in the pharma sector. The difference between the grey market premium and the listing price indicated that those who invested in the IPO could receive initial gains.
Aptus Pharma has a b strategy for the future. The company's focus is on the distribution and marketing of finished pharmaceutical formulations, which will strengthen its market position. Due to increasing investor confidence, stability and potential growth can be observed in the company's shares in the future.
